Ophthalmic deals
By BC Staff | Sep 29, 2008 | 7:00 AM GMT
Ophthalmic deals
| Date | Companies | Value [upfront; milestones/royalties] | Description |
| Sep 08 | Acucela/Otsuka (Tokyo:4768) | [$5M; up to $258M] | Partner to develop a pair of compounds for ophthalmic indications: Acucela's ACU-4429 for dry age-related macular degeneration (AMD) and potentially other indications such as diabetic retinopathy; and Otsuka's rebamipide |
| Aug 08 | Eyetech/OSI (NASDAQ:OSIP) | [$0; undisclosed] | OSI employees purchase the assets of the company's Eyetech business to form newco Eyetech Inc. which includes OSI's remaining ophthalmic assets, including U.S. rights to Macugen pegaptanib to treat wet AMD |
| Aug 08 | Asterand (LSE:ATD)/Allergan (NYSE:AGN) | [$6.3M; up to $56M] | Allergan obtains exclusive worldwide rights to undisclosed preclinical small molecule prostaglandin receptor agonists for ophthalmic indications
|
Read the full 1224 word article
